Australia's Ahpra Issues Prescribing Guidance Covering Medicinal Cannabis and Telehealth Risks
Ahpra issued guidance covering off-label, unapproved and compounded medicines, including medicinal cannabis, and warned about high-volume prescribing models. It requires individual assessment, evidence, informed consent, records and conflict management. It reiterates professional obligations rather than creating a cannabis-specific ban.
For the full article, please visit the original source link below. CannabisInsight curates and summarizes key news from the global cannabis and hemp industry.
Source
ahpra.gov.au
CannabisInsight selects and summarizes news from external sources. Copyright in the original articles remains with the respective publishers or institutions. Follow the source links for full reporting and context.
Original Link
https://www.ahpra.gov.au/News/2026-09-16-Peptide-prescribing-crackdown